Related Experiment Video
Updated: May 29, 2026
Tumor Treating Field Therapy in Combination with Bevacizumab for the Treatment of Recurrent Glioblastoma
Published on: October 27, 2014
Bevacizumab in non-small-cell lung cancer: a review
1Département de Médecine, Institut Gustave Roussy, Villejuif, France. david.planchard@igr.fr
Abstract:
Current targeted strategies for cancer focus on the blockade of growth factor receptors and the inhibition of angiogenesis. The VEGF pathway has become an attractive target in multiple malignancies, including lung cancer. Bevacizumab, a monoclonal antibody against VEGF, increased survival in non-small-cell lung cancer (NSCLC) patients when added to standard carboplatin/paclitaxel chemotherapy. The pivotal Phase III study (ECOG 4599) in NSCLC showed longer overall survival: 12.3 versus 10.3 months and a higher median progression-free survival of 6.2 versus 4.5 months when chemotherapy was associated with bevacizumab. Benefits were confirmed in terms of progression-free survival in the European Phase III study (AVAiL). Subsequently, bevacizumab gained US FDA and European Medicines Agengy approval as a first-line therapy for advanced NSCLC. Bevacizumab's safety profile is well established: most adverse events are mild to moderate and can be managed using standard interventions. This article presents an overview of the current data on bevacizumab for NSCLC.
Insights
Bevacizumab, an anti-VEGF therapy, significantly improves survival and progression-free survival for non-small-cell lung cancer (NSCLC) patients when combined with chemotherapy. Its established safety profile supports its use in advanced NSCLC.
Area of Science:
- Oncology
- Pharmacology
- Medical Research
Background:
- Targeted cancer therapies often involve blocking growth factor receptors and inhibiting angiogenesis.
- The vascular endothelial growth factor (VEGF) pathway is a key target in various cancers, including lung cancer.
Purpose of the Study:
- To present an overview of current data on bevacizumab for non-small-cell lung cancer (NSCLC).
- To highlight the efficacy and safety of bevacizumab as a targeted therapy for advanced NSCLC.
Main Methods:
- Review of pivotal Phase III clinical trials (ECOG 4599 and AVAiL).
- Analysis of survival data, including overall survival (OS) and progression-free survival (PFS).
- Evaluation of bevacizumab's safety profile in NSCLC patients.
Main Results:
- Bevacizumab added to carboplatin/paclitaxel chemotherapy increased median overall survival from 10.3 to 12.3 months in ECOG 4599.
- Median progression-free survival was extended from 4.5 to 6.2 months with bevacizumab in ECOG 4599.
- Benefits in progression-free survival were confirmed in the AVAiL study.
Conclusions:
- Bevacizumab is an effective first-line therapy for advanced NSCLC when combined with chemotherapy.
- Bevacizumab has demonstrated significant improvements in survival outcomes for NSCLC patients.
- The safety profile of bevacizumab is well-characterized and manageable.
More Related Videos
04:04Endobronchial Ultrasound-guided Intratumoral Injection of Cisplatin for the Treatment of Isolated Mediastinal Recurrence of Lung Cancer
Published on: February 12, 2017
07:42Patient-Derived Tumor Explants As a "Live" Preclinical Platform for Predicting Drug Resistance in Patients
Published on: February 7, 2021
Related Concept Videos
02:57Targeted Cancer Therapies
There are several types of targeted therapies against specific...
02:49Cancer Therapies
However, cancer treatments can pose several challenges, as therapies used to kill cancer cells are generally also toxic to normal cells. Moreover, cancer cells mutate rapidly and can develop resistance to chemical agents or radiation therapy. Besides, all types of cancer cells may not respond to the same therapy. Some cancer cells respond to one...
02:56Treatment Resistent Cancers
02:56Treatment Resistant Cancers